Tumor-induced hypophosphatemic rickets in an adolescent boy - Clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 10, 2010, Pages 4511-4517

  Haeusler, Gabriele ^a   Freilinger, M ^a   Dominkus, M ^a   Egerbacher, M ^b   Amann, G ^a   Kolb, A ^a   Schlegel, W ^a   Raimann, A ^a   Staudenherz, A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE OCTREOTIDE; 25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; CITRATE SYNTHASE; CYTOCHROME C OXIDASE; FIBROBLAST GROWTH FACTOR 23; OXIDOREDUCTASE; PARATHYROID HORMONE; PHOSPHATE; RADIOPHARMACEUTICAL AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADOLESCENT DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CARTILAGE CELL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GROWTH PLATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; HYPOPHOSPHATEMIC RICKETS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMOMA; MUSCLE TISSUE; MUSCLE WEAKNESS; OSTEOBLAST; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHYSICAL MOBILITY; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

EID: 77957772783     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0543     Document Type: Article

References (38)

1. Drezner MK 2001 Tumor-induced osteomalacia. Rev Endocr Metab Disord 2:175-186
2. Drezner M 1996 Tumour-induced osteomalacia. In: Favus M, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 3rd ed. Philadelphia: Lippincott-Raven; 319-325
3. Ward LM 2005 Renal phosphate - wasting disorders in childhood. Pediatr Endocrinol Rev 2(Suppl 3):342-350
4. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW 2004 Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1-30
5. Jan de Beur SM 2005 Tumor-induced osteomalacia. JAMA 294:1260-1267
6. Prader A, Illig R, Uehlinger E, Stalder G 1959 Rickets following bone tumor. [German] Helv Paediatr Acta 14:554-565
7. Reyes-Múgica M, Arnsmeier SL, Backeljauw PF, Persing J, Ellis B, Carpenter TO 2000 Phosphaturic mesenchymal tumor-induced rickets. Pediatr Dev Pathol 3:61-69
8. Whyte MP, Podgornik MN, Wollberg VA, Eddy MC, McAlister WH 2001 Pseudo-(tumor-induced) rickets. J Bone Miner Res 16:1564-1571
9. Ward LM, Rauch F, White KE, Filler G, Matzinger MA, Letts M, Travers R, Econs MJ, Glorieux FH 2004 Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone 34:905-911
10. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
11. Rowe PS 2004 The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15:264-281
12. Strom TM, Jüppner H 2008 PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens 17:357-362
13. Bielesz B, Klaushofer K, Oberbauer R 2004 Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 35:1229-1239
14. Weidner N, Bar RS, Weiss D, Strottmann MP 1985 Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55:1691-1705
15. Weidner N, Santa Cruz D 1987 Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59:1442-1454
16. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A 1998 Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233-245 (Pubitemid 28317526)
17. Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA 2002 Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:761-763
18. Casari S, Rossi V, Varenna M, Gasparini M, Parafioriti A, Failoni S, Sinigaglia L 2003 A case of oncogenic osteomalacia detected by 111 In-pentetreotide total body scan. Clin Exp Rheumatol 21:493-496
19. Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M, Sasaki H, Suzuki H, Ito N, Fukumoto S, Nanjo K 2008 Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med 47:957-961
20. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H 2001 Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
21. Rossmanith W, Raffelsberger T, Roka J, Kornek B, Feucht M, Bittner RE 2003 The expanding mutational spectrum of MERRF substitution G8361A in the mitochondrial tRNALys gene. Ann Neurol 54:820-823
22. Bahrami A, Weiss SW, Montgomery E, Horvai AE, Jin L, Inwards CY, Folpe AL 2009 RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 33:1348-1354
23. Kuwertz-Bröking E, Koch HG, Marquardt T, Rossi R, Helmchen U, Müller-Höcker J, Harms E, Bulla M 2000 Renal Fanconi syndrome: first sign of partial respiratory chain complex IV deficiency. Pediatr Nephrol 14:495-498
24. Mihai CM, Catrinoiu D, Toringhibel M, Stoicescu RM, Hancu A 2009 De Toni-Debre-Fanconi syndrome in a patient with Kearns-Sayre syndrome: a case report. J Med Case Reports 3:101
25. Odièvre MH, Lombès A, Dessemme P, Santer R, Brivet M, Chevallier B, Lagardère B, Odièvre M 2002 A secondary respiratory chain defect in a patient with Fanconi-Bickel syndrome. J Inherit Metab Dis 25:379-384
26. Rago RP, Miles JM, Sufit RL, Spriggs DR, Wilding G 1994 Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. Cancer 73:1954-1959
27. Reubi JC, Schaer JC, Laissue JA, Waser B 1996 Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45:39-41
28. Avila NA, Skarulis M, Rubino DM, Doppman JL 1996 Oncogenic osteomalacia: lesion detection by MR skeletal survey. AJR Am J Roentgenol 167:343-345
29. Hodgson SF, Clarke BL, Tebben PJ, Mullan BP, Cooney 3rd WP, Shives TC 2006 Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract 12:35-42
30. Kimizuka T, Ozaki Y, Sumi Y 2004 Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia. Ann Nucl Med 18:63-67
31. Mackie EJ, Trechsel U, Bruns C 1990 Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation. Development 110:1233-1239
32. Very NM, Kittilson JD, Klein SE, Sheridan MA 2008 Somatostatin inhibits basal and growth hormone-stimulated hepatic insulin-like growth factor-I production. Mol Cell Endocrinol 281:19-26
33. Hagemeister AL, Sheridan MA 2008 Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways. Am J Physiol Regul Integr Comp Physiol 295:R490-497
34. Zapf J, Gosteli-Peter M, Weckbecker G, Hunziker EB, Reinecke M 2002 The somatostatin analog octreotide inhibits GH-stimulated, but not IGF-I-stimulated, bone growth in hypophysectomized rats. Endocrinology 143:2944-2952
35. Klein SE, Sheridan MA 2008 Somatostatin signaling and the regulation of growth and metabolism in fish. Mol Cell Endocrinol 286:148-154
36. Fukumoto S 2008 Physiological regulation and disorders of phosphate metabolism - pivotal role of fibroblast growth factor 23. Intern Med 47:337-343
37. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N 2007 Mineralized tissue cells are a principal source of FGF23. Bone 40:1565-1573
38. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692